85 results
8-K
EX-10.3
NBSE
NeuBase Therapeutics Inc
30 Jun 23
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
4:21pm
possible under the circumstances taking into account the Company’s good faith assessment of any adverse consequences to the Company and its
10-QT
NBSE
NeuBase Therapeutics Inc
5 Jun 23
Quarterly report for transitional period
4:05pm
in their entirety based on the lowest level of input that is significant to the fair value measurement. Management’s assessment of the significance
8-K
EX-1.1
9ob1sw7crre5qqpkbpql
27 Aug 21
Entry into a Material Definitive Agreement
12:00am
424B5
36h6gtlm8czyv
23 Apr 21
Prospectus supplement for primary offering
4:05pm
8-K
EX-1.1
n6kkc0
22 Apr 21
NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock
9:33am
424B5
erjmx
21 Apr 21
Prospectus supplement for primary offering
4:03pm